[1]
|
Fiona André, B.C.B. (2022) Sjögren’s Syndrome. Journal der Deutschen Dermatologischen Gesellschaft, 20, 980-1002.
https://doi.org/10.1111/ddg.14823
|
[2]
|
Ramos-Casals, M., Brito-Zerón, P., Sisó-Almirall, A. and Bosch, X. (2012) Primary Sjogren Syndrome. BMJ, 344, e3821. https://doi.org/10.1136/bmj.e3821
|
[3]
|
Alunno, A., Carubbi, F., Bartoloni, E., Cipriani, P., Giacomelli, R. and Gerli, R. (2019) The Kaleidoscope of Neurological Manifestations in Primary Sjögren’s Syndrome. Clinical and Experimental Rheumatology, 37, 192-198.
|
[4]
|
Seeliger, T., et al. (2023) Sjögren’s Syndrome with and without Neurological Involvement. Journal of Neurology, 270, 2987-2996. https://doi.org/10.1007/s00415-023-11613-5
|
[5]
|
杨丹, 乔琳, 赵丽丹. 原发干燥综合征伴发脑梗塞1例报告附文献复习[J]. 北京大学学报, 2016, 48(6): 1077-1080.
|
[6]
|
Chai, J. and Logigian, E.L. (2010) Neurological Mani-festations of Primary Sjögren’s Syndrome. Current Opinion in Neurology, 23, 509-513. https://doi.org/10.1097/WCO.0b013e32833de6ab
|
[7]
|
Negrini, S., Emmi, G., Greco, M., et al. (2022) Sjögren’s Syndrome: A Systemic Autoimmune Disease. Clinical and Experimental Medicine, 22, 9-25. https://doi.org/10.1007/s10238-021-00728-6
|
[8]
|
André, F. and Böckle, B.C. (2022) Sjögren’s Syndrome. Journal der Deutschen Dermatologischen Gesellschaft, 20, 980-1002. https://doi.org/10.1111/ddg.14823
|
[9]
|
De Seze, J., Delalande, S., Fauchais, A.L., et al. (2006) Myelopathies Secondary to Sjögren’s Syndrome: Treatment with Monthly Intravenous Cyclophosphamide Associated with Corticosteroids. The Journal of Rheumatology, 33, 709-711.
|
[10]
|
Hagiwara, K., et al. (2008) Upper Motor Neuron Syndrome Associated with Subclinical Sjögren’s Syn-drome. Internal Medicine, 47, 1047-1051. https://doi.org/10.2169/internalmedicine.47.0846
|
[11]
|
Zahlane, S., Louhab, N., El Mellakh, M. and Kissani, N. (2016) Anterior Horn Syndrome: A Rare Manifestation of Primary Sjögren’s Syndrome. Joint Bone Spine, 83, 448-450. https://doi.org/10.1016/j.jbspin.2016.02.018
|
[12]
|
Chandra, M.S., et al. (2022) Primary Sjögren’s Syndrome Presenting as Cerebral Venous Thrombosis: A Rare Case. Cureus, 14, E28772. https://doi.org/10.7759/cureus.28772
|
[13]
|
Ramos-Casals, M., Brito-Zerón, P., Solans, R., et al. (2014) Systemic Involvement in Primary Sjögren’s Syndrome Evaluated by the EULAR-SS Disease Activity Index: Analysis of 921 Spanish Patients (GEAS-SS Registry). Rheumatology (Oxford), 53, 321-331. https://doi.org/10.1093/rheumatology/ket349
|
[14]
|
Ramos-Casals, M., et al. (2012) Topical and Systemic Medica-tions for the Treatment of Primary Sjögren’s Syndrome. Nature Reviews Rheumatology, 8, 399-411. https://doi.org/10.1038/nrrheum.2012.53
|
[15]
|
Morreale, M., Marchione, P., Giacomini, P., et al. (2014) Neuro-logical Involvement in Primary Sjögren Syndrome: A Focus on Central Nervous System. PLOS ONE, 9, e84605. https://doi.org/10.1371/journal.pone.0084605
|
[16]
|
Josephs, K.A., Rubino, F.A. and Dickson, D.W. (2004) Nonvasculitic Autoimmune Inflammatory Meningoencephalitis. Neuropathology, 24, 149-152. https://doi.org/10.1111/j.1440-1789.2004.00542.x
|
[17]
|
Jamilloux, Y., Magy, L., Hurtevent, J.F., et al. (2014) Immunological Profiles Determine Neurological Involvement in Sjögren’s Syndrome. European Journal of Internal Medicine, 25, 177-181. https://doi.org/10.1016/j.ejim.2013.10.005
|
[18]
|
Sakai, A., Sugawara, Y., Kuroishi, T., Sasano, T. and Sugawara, S. (2008) Identification of IL-18 and Th17 Cells in Salivary Glands of Patients with Sjögren’s Syndrome, and Amplification of IL-17-Mediated Secretion of Inflammatory Cytokines from Salivary Gland Cells by IL-18. The Journal of Immunology, 181, 2898-2906.
https://doi.org/10.4049/jimmunol.181.4.2898
|
[19]
|
Katsifis, G.E., Rekka, S., Moutsopoulos, N.M., Pillemer, S. and Wahl, S.M. (2009) Systemic and Local Interleukin-17 and Linked Cytokines Associated with Sjögren’s Syndrome Immunopathogenesis. The American Journal of Pathology, 175, 1167-1177. https://doi.org/10.2353/ajpath.2009.090319
|
[20]
|
Nocturne, G. and Mariette, X. (2013) Advances in Understanding the Pathogenesis of Primary Sjögren’s Syndrome. Nature Reviews Rheumatology, 9, 544-556. https://doi.org/10.1038/nrrheum.2013.110
|
[21]
|
Sarigul, M., et al. (2010) The Numbers of Foxp3+ Treg Cells Are Positively Correlated with Higher Grade of Infiltration at the Salivary Glands in Primary Sjögren’s Syndrome. Lupus, 19, 138-145.
https://doi.org/10.1177/0961203309348234
|
[22]
|
Fan, G., Dai, F., Chen, S., et al. (2021) Neurological Involvement in Patients with Primary Sjögren’s Syndrome. Journal of Clinical Rheumatology, 27, 50-55. https://doi.org/10.1097/RHU.0000000000001128
|
[23]
|
Rajagopala, S., Danigeti, G. and Subrahmanyan, D. (2015) An Unusually Dry Story. Indian Journal of Critical Care Medicine, 19, 550-553. https://doi.org/10.4103/0972-5229.164808
|
[24]
|
Ichikawa, H., Ishihara, K., Fujimoto, R., et al. (2004) An Autop-sied Case of Sjögren’s Syndrome with Massive Necrotic and Demyelinating Lesions of the Cerebellar White Matter. Journal of the Neurological Sciences, 225, 143-148.
https://doi.org/10.1016/j.jns.2004.07.010
|
[25]
|
Meheroz, H., Rabadi, S.K. and Brett, D. (2010) Neurological Pic-tures. Primary Sjögren Syndrome Presenting as Neuromyelitis Optica. Journal of Neurology Neurosurgery and Psy-chiatry, 81, 213-214.
https://doi.org/10.1136/jnnp.2009.183913
|
[26]
|
Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., et al. (2020) EULAR Recommendations for the Management of Sjögren’s Syndrome with Topical and Systemic Therapies. Annals of the Rheumatic Diseases, 79, 3-18.
https://doi.org/10.1136/annrheumdis-2019-216114
|
[27]
|
Radaelli, M., Moiola, L., Sangalli, F., et al. (2016) Neuromyelitis Optica Spectrum Disorders: Long-Term Safety and Efficacy of Rituximab in Caucasian Patients. Multiple Sclerosis, 22, 511-519.
https://doi.org/10.1177/1352458515594042
|